Drug intelligence / Profile preview

VTX-041

Development stage: Preclinical
Lead developer: Vita Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Cell Therapies
Administration: Oral

Overview

VTX-041 is an autologous cell therapy developed by Vita Therapeutics for the treatment of limb-girdle muscular dystrophy type 2A/R1 (LGMD2A/R1). This therapy leverages CRISPR gene editing technology to insert a functional CAPN3 gene into stem cells derived from the patient. The approach aims to overcome the challenges associated with systemic delivery of the large CAPN3 gene, facilitating targeted muscle repair.

Beyond the preview

Go deeper on VTX-041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX-041.

Explore the full profile